Disease · MONDO_0011849
Targets102
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 102
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 10 | Glucocorticoid receptor agonist | Approval | https://conductscience.org/library/genes/2908 | Drugs and targets |
| IL17A | Interleukin-17A | 8 | Interleukin 17A inhibitor | Approval | https://conductscience.org/library/genes/3605 | Drugs and targets |
| TNF | Tumor necrosis factor | 6 | TNF-alpha inhibitor | Approval | https://conductscience.org/library/genes/7124 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 6 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator | Approval | https://conductscience.org/library/genes/7297 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 5 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Approval | https://conductscience.org/library/genes/3716 | Drugs and targets |
| IL12B | Interleukin-12 | 4 | Interleukin-12 inhibitor; Interleukin-23 inhibitor | Approval | https://conductscience.org/library/genes/3593 | Drugs and targets |
| IL23A | Interleukin-23 | 4 | Interleukin-23 inhibitor | Approval | https://conductscience.org/library/genes/51561 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 4 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Approval | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 4 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor | Approval | https://conductscience.org/library/genes/3718 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 2 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| GLP1R | Glucagon-like peptide 1 receptor | 2 | Glucagon-like peptide 1 receptor agonist | Phase 3 | https://conductscience.org/library/genes/2740 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 2 | HMG-CoA reductase inhibitor | Unknown | https://conductscience.org/library/genes/3156 | Drugs and targets |
| IL17F | Interleukin-17F | 2 | Interleukin-17F inhibitor | Phase 3 | https://conductscience.org/library/genes/112744 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5743 | Drugs and targets |
| CD2 | T-cell surface antigen CD2 | 1 | T-cell surface antigen CD2 inhibitor | Phase 2 | https://conductscience.org/library/genes/914 | Drugs and targets |
| CD3E | T-cell surface glycoprotein CD3 epsilon chain | 1 | T-cell surface glycoprotein CD3 epsilon chain other | Phase 2 | https://conductscience.org/library/genes/916 | Drugs and targets |
| CD40 | Tumor necrosis factor receptor superfamily member 5 | 1 | Tumor necrosis factor receptor superfamily member 5 inhibitor | Phase 1 | https://conductscience.org/library/genes/958 | Drugs and targets |
| CD80 | T-lymphocyte activation antigen CD80 | 1 | T-lymphocyte activation antigen CD80 inhibitor | Approval | https://conductscience.org/library/genes/941 | Drugs and targets |
| CD86 | T-lymphocyte activation antigen CD86 | 1 | T-lymphocyte activation antigen CD86 inhibitor | Approval | https://conductscience.org/library/genes/942 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011849/targets